00014792909/9/2024FALSE00014792902024-09-092024-09-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 9, 2024
Revance Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3629777-0551645
(State or other jurisdiction of incorporation)(Commission File No.)(I.R.S. Employer Identification No.)
1222 Demonbreun Street, Suite 2000, Nashville, Tennessee, 37203
(Address of principal executive offices and zip code)

(615) 724-7755
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueRVNCNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Item 8.01    Other Events

On September 9, 2024, Revance Therapeutics, Inc. (the “Company”) announced that China’s National Medical Products Administration approved Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.’s, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., biologics license application for DaxinbotulinumtoxinA for Injection for the improvement of glabellar lines.




SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:September 9, 2024Revance Therapeutics, Inc.
By:/s/ Tobin C. Schilke
Tobin C. Schilke
Chief Financial Officer


v3.24.2.u1
Cover Page Document
Sep. 09, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 09, 2024
Entity Registrant Name Revance Therapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36297
Entity Tax Identification Number 77-0551645
Entity Address, Address Line One 1222 Demonbreun Street, Suite 2000
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code 615
Local Phone Number 724-7755
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol RVNC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001479290
Amendment Flag false
Revance Therapeutics (NASDAQ:RVNC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024 Haga Click aquí para más Gráficas Revance Therapeutics.
Revance Therapeutics (NASDAQ:RVNC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024 Haga Click aquí para más Gráficas Revance Therapeutics.